Skip to main content
    A

    Armata Pharmaceuticals Inc (ARMP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $2.99
    -0.88 (-22.74%)

    Market Cap: $143.94M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Armata Pharmaceuticals Inc (ARMP) Financials: Revenue, Profit and Cash Flow

    Updated Nov 12, 2026. Financial statements from company filings, amounts in US dollars.

    Armata Pharmaceuticals reported revenue of $4.90M for the fiscal year ended Dec 31, 2025, down 5.2% from the year before. That year, net income was -$173.80M with a net margin of -3544.0%, operating cash flow was -$25.76M and free cash flow was -$26.30M. The quarter ended Sep 30, 2026 had revenue of $3.17M and net income of $54.86M.

    Revenue and Margins

    Over the 9 years to Dec 2025, revenue grew from $260.00K, a compound annual rate of 38.6%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$4.90M-5.2%100.0%-747.0%-3544.0%
    Dec 2024$5.17M+14.2%100.0%-820.2%-365.6%
    Dec 2023$4.53M-17.8%100.0%-902.8%-1524.5%
    Dec 2022$5.51M+23.1%100.0%-670.8%-670.2%
    Dec 2021$4.47M+443.6%100.0%-532.5%-517.5%
    Dec 2020$823.00KN/A100.0%-2623.0%-2695.1%
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0-100.0%N/AN/AN/A
    Dec 2017$115.00K-55.8%100.0%-14048.7%-11163.5%
    Dec 2016$260.00KN/A100.0%-8991.5%-7245.4%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$4.90M$5.17M$4.53M$5.51M$4.47M$823.00K$0$0$115.00K$260.00K
    Gross profit$4.90M$5.17M$4.53M$5.51M$4.47M$823.00K$0$0$115.00K$260.00K
    Research and development$23.72M$34.43M$33.77M$35.02M$20.02M$14.44M$9.82M$15.14M$2.88M$5.68M
    Operating income-$36.63M-$42.44M-$40.89M-$36.95M-$23.82M-$21.59M-$19.75M-$17.66M-$16.16M-$23.38M
    Net income-$173.80M-$18.92M-$69.05M-$36.92M-$23.16M-$22.18M-$19.48M-$16.70M-$12.84M-$18.84M
    EBITDAN/A-$19.76MN/A-$36.05M-$21.93M-$20.47M-$17.29M-$14.50M-$13.78M-$19.02M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$3.17M$2.51M$789.00K$1.08M$1.16M$2.17M$491.00K$1.24M$2.97M$0$966.00K$1.53M
    Gross profit$3.17M$2.51M$789.00K$1.08M$1.16M$2.17M$491.00K$1.24M$2.97M$0$966.00K$1.53M
    Operating income-$7.38M-$10.31M-$8.79M-$13.82M-$7.78M-$6.84M-$8.19M-$10.54M-$9.76M-$11.91M-$10.23M-$9.58M
    Net income$54.86M$74.14M-$115.35M-$124.30M-$26.68M-$16.30M-$6.53M$2.60M-$5.48M$8.99M-$25.02M-$19.85M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $256.92M exceeded cash and equivalents by $248.23M. Shareholder equity was negative, at -$218.60M, as total liabilities of $295.48M exceeded total assets of $76.88M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$76.88M$86.44M$98.36M$95.83M$69.77M$39.52M$25.45M$14.54M$11.14M$18.15M
    Current assets$10.67M$11.31M$19.15M$27.05M$14.99M$10.85M$6.66M$10.36M$5.38M$6.31M
    Cash and equivalents$8.69M$9.29M$13.52M$14.85M$10.29M$9.65M$6.03M$9.66M$5.13M$5.71M
    Total liabilities$295.48M$134.46M$130.43M$59.75M$44.37M$20.66M$10.86M$6.85M$3.41M$8.43M
    Short-term debt$0$38.95M$0$17.01M$3.02M$1.94M$970.00K$970.00K$0$803.00K
    Long-term debt$256.92M$55.44M$82.31M$0N/AN/AN/AN/AN/AN/A
    Shareholder equity-$218.60M-$48.02M-$32.06M$36.08M$25.40M$18.86M$14.59M$7.69M$7.73M$9.72M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$84.48M$89.95M$69.80M$76.88M$89.52M$80.79M$87.25M$86.44M$98.24M$108.31M$120.36M$98.36M
    Total liabilities$258.61M$321.12M$381.39M$295.48M$185.10M$150.29M$141.03M$134.46M$149.21M$154.41M$176.87M$130.43M
    Cash and equivalents$18.32M$23.95M$4.75M$8.69M$14.76M$4.33M$11.69M$9.29M$17.14M$26.41M$37.86M$13.52M
    Shareholder equity-$174.13M-$231.17M-$311.59M-$218.60M-$95.59M-$69.50M-$53.78M-$48.02M-$50.97M-$46.10M-$56.51M-$32.06M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$25.76M-$37.55M-$47.42M-$32.48M-$23.57M-$18.27M-$15.58M-$10.63M-$9.19M-$10.61M
    Capital expenditures$542.00K$1.88M$8.14M$2.21M$1.30M$824.00K$224.00K$875.00K$58.00K$279.00K
    Free cash flow-$26.30M-$39.43M-$55.57M-$34.69M-$24.88M-$19.09M-$15.81M-$11.50M-$9.25M-$10.88M
    Dividends paidN/AN/AN/AN/AN/AN/AN/AN/A$0$80.00K
    Investing cash flow-$542.00K-$1.88M-$8.13M-$2.21M-$1.30M-$824.00K$2.88M$8.81M-$58.00K-$279.00K
    Financing cash flow$25.61M$34.96M$53.99M$44.02M$25.52M$23.21M$8.97M$0$8.67M$7.23M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$5.52M-$8.67M-$5.78M-$6.67M-$4.30M-$7.21M-$7.58M-$7.93M-$8.86M-$10.18M-$10.58M-$8.11M
    Capital expenditures$91.00K$17.00K$63.00K$52.00K$242.00K$149.00K$99.00K$77.00K$340.00K$1.37M$250.00K$2.40M
    Free cash flow-$5.61M-$8.68M-$5.84M-$6.73M-$4.54M-$7.36M-$7.68M-$8.00M-$9.20M-$11.54M-$10.83M-$10.51M
    Last 12 quarters

    Frequently Asked Questions About ARMP

    What is Armata Pharmaceuticals' annual revenue?

    Armata Pharmaceuticals reported revenue of $4.90M for the fiscal year ended Dec 31, 2025.

    How fast is Armata Pharmaceuticals' revenue growing?

    Revenue was down 5.2% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -3.8%.

    Is Armata Pharmaceuticals profitable?

    No. Armata Pharmaceuticals reported net income of -$173.80M for the fiscal year ended Dec 31, 2025, with a net margin of -3544.0%.

    How much free cash flow does ARMP generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$25.76M minus capital expenditures of $542.00K produced free cash flow of -$26.30M.

    How much debt does Armata Pharmaceuticals have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $256.92M, short-term debt of $0 and cash and equivalents of $8.69M.